keyword
MENU ▼
Read by QxMD icon Read
search

Oncotype

keyword
https://www.readbyqxmd.com/read/28192639/a-deep-learning-based-strategy-for-identifying-and-associating-mitotic-activity-with-gene-expression-derived-risk-categories-in-estrogen-receptor-positive-breast-cancers
#1
David Romo-Bucheli, Andrew Janowczyk, Hannah Gilmore, Eduardo Romero, Anant Madabhushi
The treatment and management of early stage estrogen receptor positive (ER+) breast cancer is hindered by the difficulty in identifying patients who require adjuvant chemotherapy in contrast to those that will respond to hormonal therapy. To distinguish between the more and less aggressive breast tumors, which is a fundamental criterion for the selection of an appropriate treatment plan, Oncotype DX (ODX) and other gene expression tests are typically employed. While informative, these gene expression tests are expensive, tissue destructive, and require specialized facilities...
February 13, 2017: Cytometry. Part A: the Journal of the International Society for Analytical Cytology
https://www.readbyqxmd.com/read/28168058/correlation-of-oncotype-dx-recurrence-score-with-histomorphology-and-immunohistochemistry-in-over-500-patients
#2
Matthew G Hanna, Ira J Bleiweiss, Anupma Nayak, Shabnam Jaffer
Oncotype Dx is used to determine the recurrence risk (RR) in patients with estrogen receptor positive (ER+) and lymph node negative (LN-) breast cancer. The RR is divided into low (0-17), intermediate (18-30), and high (31) to predict chemotherapy benefit. Our goal was to determine the association between histomorphology, immunohistochemistry, and RR. We retrospectively identified 536 patients with ER+ and LN- breast cancers that underwent Oncotype testing from 2006 to 2013. Tumor size ranged from 0.2 cm to 6...
2017: International Journal of Breast Cancer
https://www.readbyqxmd.com/read/28153508/tumor-infiltrating-lymphocytes-are-significantly-associated-with-better-overall-survival-and-disease-free-survival-in-triple-negative-but-not-estrogen-receptor-positive-breast-cancers
#3
Uma Krishnamurti, Ceyda Sonmez Wetherilt, Jing Yang, Limin Peng, Xiaoxian Li
Correlation between tumor-infiltrating lymphocytes (TILs) and complete pathological response (pCR) in breast cancers in neoadjuvant settings has been reported. In this study, we analyzed the association between TILs and diagnostic and prognostic parameters in estrogen receptor positive (ER+) and triple-negative breast cancer (TNBC) without neoadjuvant treatments. Three hundred and forty-four (344) patients who underwent mastectomy for breast cancer (187 ER+ and 157 TNBC) without neoadjuvant treatments were evaluated...
January 30, 2017: Human Pathology
https://www.readbyqxmd.com/read/28152871/breast-cancer-specific-mortality-in-patients-with-early-stage-hormone-receptor-positive-invasive-breast-cancer-and-oncotype-dx-recurrence-score-results-in-the-seer-database
#4
Valentina Petkov, Dave P Miller, Nadia Howlader, Nathan Gliner, Will Howe, Nicola C Schussler, Kathleen Cronin, Frederick L Baehner, Lynne Penberthy
: 176 Background: NCI's SEER Program provides cancer incidence and survival statistics for ~28% of the US. New research models are needed to characterize the use and impact of genomic tests on patient outcomes. Genomic Health and SEER collaborated to electronically supplement SEER registries with Recurrence Score (RS) results, and have evaluated breast cancer specific mortality (BCSM) in early stage hormone receptor (HR)+ HER2- invasive breast cancer. METHODS: Pts were eligible for pre-specified node negative (N-) disease analysis if HR+, HER2- (by RT-PCR), no prior malignancy, 40-85 years of age, and diagnosed between Jan 2004 (Oncotype DX available Jan 2004) and Dec 2011 (SEER survival analysis complete through 2012)...
March 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28152707/chemotherapy-costs-associated-with-receipt-of-the-adoption-of-oncotype-dx-in-early-stage-breast-cancer-within-the-seer-medicare-population
#5
Xiaojuan Mi, Shelby D Reed, Gary H Lyman, Lesley H Curtis
: 32 Background: The Oncotype DX (ODX) multigene assay has been previously suggested to result in an overall reduction in the use of adjuvant chemotherapy and associated costs for women with early stage, estrogen receptor (ER)-positive breast cancer. However, the association between adoption of ODX and chemotherapy costs has only previously been considered in theoretical models and has not been examined using actual patient outcomes in real world clinical practice. METHODS: Retrospective analysis of Surveillance, Epidemiology, and End Results (SEER) -Medicare data of the association between overall and chemotherapy-specific costs associated with adoption of ODX testing in patients diagnosed with invasive, non-metastatic, ER-positive breast cancer between 2005 and 2009...
March 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28152060/expression-quantitative-trait-loci-qtl-in-tumor-adjacent-normal-breast-tissue-and-breast-tumor-tissue
#6
Alejandro Quiroz-Zárate, Benjamin J Harshfield, Rong Hu, Nick Knoblauch, Andrew H Beck, Susan E Hankinson, Vincent Carey, Rulla M Tamimi, David J Hunter, John Quackenbush, Aditi Hazra
We investigate 71 single nucleotide polymorphisms (SNPs) identified in meta-analytic studies of genome-wide association studies (GWAS) of breast cancer, the majority of which are located in intergenic or intronic regions. To explore regulatory impacts of these variants we conducted expression quantitative loci (eQTL) analyses on tissue samples from 376 invasive postmenopausal breast cancer cases in the Nurses' Health Study (NHS) diagnosed from 1990-2004. Expression analysis was conducted on all formalin-fixed paraffin-embedded (FFPE) tissue samples (and on 264 adjacent normal samples) using the Affymetrix Human Transcriptome Array...
2017: PloS One
https://www.readbyqxmd.com/read/28145091/low-utility-of-oncotype-dx%C3%A2-in-the-clinic
#7
Luisel J Ricks-Santi, John Tyson McDonald
Precision medicine tools are currently making their way into the clinic and being utilized to diagnose, prognose, and individualize cancer care. The multi-gene expression-based assay, Oncotype DX® (ODX), is a genomic tumor profiling tool that determines the expression of 21 tumor- associated genes; it helps determine the risk for distant recurrence and whether chemotherapy is an appropriate course of treatment in patients with early stage, estrogen receptor (ER) positive, HER2 negative, and lymph node negative (or 1-3 positive lymph nodes) invasive BCa...
February 1, 2017: Cancer Medicine
https://www.readbyqxmd.com/read/28132956/multigene-expression-assay-and-benefit-of-radiotherapy-after-breast-conservation-in-ductal-carcinoma-in-situ
#8
Eileen Rakovitch, Sharon Nofech-Mozes, Wedad Hanna, Rinku Sutradhar, Frederick L Baehner, Dave P Miller, Cindy Fong, Sumei Gu, Alan Tuck, Sandip Sengupta, Leela Elavathil, Prashant A Jani, Michel Bonin, Martin C Chang, Elzbieta Slodkowska, Joseph M Anderson, Diana B Cherbavaz, Steven Shak, Lawrence Paszat
BACKGROUND: Most women with ductal carcinoma in situ (DCIS) will receive breast-conserving surgery (BCS) and radiation (RT). RT can be omitted for women at low risk of local recurrence (LR). The Oncotype DX DCIS score (DS) predicts LR risk after BCS alone. This study assesses the impact of RT and DS on LR risk. METHODS: Population-based cohort analysis of individuals with DCIS treated by BCS ± RT from 1994-2003. Treatment and outcomes were determined by linkage and chart review...
April 2017: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/28120435/oncotype-dx-recurrence-score-among-brca1-2-germline-mutation-carriers-with-hormone-receptors-positive-breast-cancer
#9
Naama Halpern, Amir Sonnenblick, Beatrice Uziely, Luba Divinsky, Yael Goldberg, Tamar Hamburger, Tamar Peretz, Luna Kadouri
Gene expression assays are widely used to predict risk of recurrence in early breast cancer (BC). We report the 21-gene expression assay (Oncotype Dx) recurrence score (RS) distribution of 27 BRCA carriers with estrogen receptor (ER) positive BCs, identified at Hadassah Medical Center, combined with 2 previous studies. Treatment decision and outcomes of the 27 BRCA carriers were compared with an Israeli cohort of 1594 patients published recently. We found Oncotype Dx RS low (<18), intermediate (18-30), and high (>30) among 12 (21...
January 24, 2017: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/28111076/impact-of-oncotype-dx-breast-recurrence-score-testing-on-adjuvant-chemotherapy-use-in-early-breast-cancer-real-world-experience-in-greater-manchester-uk
#10
J Loncaster, A Armstrong, S Howell, G Wilson, R Welch, A Chittalia, W J Valentine, N J Bundred
BACKGROUND: The National Institute for Health and Clinical Excellence (NICE) recommended the Oncotype DX(®) Breast Recurrence Score(®) (RS) assay as an option for informing adjuvant chemotherapy decisions in node-negative, oestrogen receptor (ER)+, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer assessed to be at intermediate risk of recurrence based on clinicopathological factors. We evaluated the impact of RS testing on adjuvant chemotherapy decision-making in routine clinical practice in a UK Cancer Network...
January 9, 2017: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28099153/building-personalized-treatment-plans-for-early-stage-colorectal-cancer-patients
#11
Hung-Hsin Lin, Nien-Chih Wei, Teh-Ying Chou, Chun-Chi Lin, Yuan-Tsu Lan, Shin-Ching Chang, Huann-Sheng Wang, Shung-Haur Yang, Wei-Shone Chen, Tzu-Chen Lin, Jen-Kou Lin, Jeng-Kai Jiang
We developed a series of models to predict the likelihood of recurrence and the response to chemotherapy for the personalized treatment of stage I and II colorectal cancer patients. A recurrence prediction model was developed from 235 stage I/II patients. The model successfully distinguished between high-risk and low-risk groups, with a hazard ratio of recurrence of 4.66 (p < 0.0001). More importantly, the model was accurate for both stage I (hazard ratio = 5.87, p = 0.0006) and stage II (hazard ratio = 4...
January 13, 2017: Oncotarget
https://www.readbyqxmd.com/read/28097781/an-analysis-of-oncotype-dx-recurrence-scores-and-clinicopathologic-characteristics-in-invasive-lobular-breast-cancer
#12
Jesse L Felts, Junjia Zhu, Bing Han, Stanley J Smith, Cristina I Truica
The Oncotype DX breast cancer assay (Genomic Health, Redwood City, CA) is increasingly being used to guide treatment decisions for patients with early stage, hormone-positive, Her-2-negative breast cancer. The utility of the Oncotype DX in decision making for treatment of invasive lobular carcinoma (ILC) has not been investigated as the results reported by Genomic Health are largely in a population with invasive ductal carcinoma (IDC). The authors hypothesized that the Oncotype DX recurrence score (RS) distribution for ILC is different than that for IDC...
January 18, 2017: Breast Journal
https://www.readbyqxmd.com/read/28087099/prognostic-and-predictive-indicators-in-early-stage-breast-cancer-and-the-role-of-genomic-profiling-focus-on-the-oncotype-dx-%C3%A2-breast-recurrence-score-assay
#13
E Curtit, L Mansi, Y Maisonnette-Escot, J-L Sautière, X Pivot
Although useful prognostic and predictive insights can be gained from patient and tumour characteristics in early-stage breast cancer, it is not always straightforward to predict the likely risk of recurrence for each individual patient following breast surgery. One of the most difficult challenges faced by clinicians is identifying patients who may benefit most from adjuvant chemotherapy, and distinguishing these cases from those where endocrine therapy may be sufficient for cure. Genomic tests such as the Oncotype DX(®) Breast Recurrence Score(®) Assay have been developed to provide a robust and clinically validated assessment of a patient's individual tumour signature...
December 14, 2016: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28064383/algorithms-for-prediction-of-the-oncotype-dx-recurrence-score-using-clinicopathologic-data-a-review-and-comparison-using-an-independent-dataset
#14
REVIEW
Michael R Harowicz, Timothy J Robinson, Michaela A Dinan, Ashirbani Saha, Jeffrey R Marks, P Kelly Marcom, Maciej A Mazurowski
PURPOSE: Given the potential savings in cost and resource utilization, several algorithms have been proposed to predict Oncotype DX recurrence score (ODX RS) using commonly acquired histopathologic variables. Although it is promising, additional independent validation of these surrogate markers is needed prior to guide the patient management. METHODS: In this retrospective study, we analyzed 305 patients with invasive breast cancer at our institution who had ODX RS available...
January 7, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/27998227/optimizing-the-use-of-gene-expression-profiling-in-early-stage-breast-cancer
#15
Hyun-Seok Kim, Christopher B Umbricht, Peter B Illei, Ashley Cimino-Mathews, Soonweng Cho, Nivedita Chowdhury, Maria Cristina Figueroa-Magalhaes, Catherine Pesce, Stacie C Jeter, Charles Mylander, Martin Rosman, Lorraine Tafra, Bradley M Turner, David G Hicks, Tyler A Jensen, Dylan V Miller, Deborah K Armstrong, Roisin M Connolly, John H Fetting, Robert S Miller, Ben Ho Park, Vered Stearns, Kala Visvanathan, Antonio C Wolff, Leslie Cope
Purpose Gene expression profiling assays are frequently used to guide adjuvant chemotherapy decisions in hormone receptor-positive, lymph node-negative breast cancer. We hypothesized that the clinical value of these new tools would be more fully realized when appropriately integrated with high-quality clinicopathologic data. Hence, we developed a model that uses routine pathologic parameters to estimate Oncotype DX recurrence score (ODX RS) and independently tested its ability to predict ODX RS in clinical samples...
December 20, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27972445/economic-assessment-of-routine-oncotype-dx-testing-of-estrogen-receptor-positive-er-early-breast-cancer-ebc-patients-with-grade-2-tumours-in-czech-republic
#16
K Hejduk, K Petrakova, L Petruzelka, Z Bielcikova, I Kolarova, J Finek, M Burger, P Ovesná, I Feigler, J Silar, Z Zbozinkova
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27958190/oncologists-barriers-and-facilitators-for-oncotype-dx-use-qualitative-study
#17
Megan C Roberts, Amy Bryson, Morris Weinberger, Stacie B Dusetzina, Michaela A Dinan, Katherine Reeder-Hayes, Stephanie B Wheeler
BACKGROUND: Oncotype DX (ODX), a tumor gene profiling test, has been incorporated into clinical guidelines to aid in adjuvant chemotherapy decision making for early-stage, hormone receptor positive breast cancer patients. Despite United States (U.S.) guidelines, less than half of eligible women receive testing. Reasons for low usage are unclear: Our objective was to better understand U.S. oncologists' ODX uptake and how they use ODX during adjuvant chemotherapy decision making. METHODS: We conducted semi-structured, ~30-minute phone interviews with medical and surgical oncologists in one U...
January 2016: International Journal of Technology Assessment in Health Care
https://www.readbyqxmd.com/read/27956536/factors-associated-with-delays-in-chemotherapy-initiation-among-patients-with-breast-cancer-at-a-comprehensive-cancer-center
#18
Katya Losk, Ines Vaz-Luis, Kristen Camuso, Rafael Batista, Max Lloyd, Mustafa Tukenmez, Mehra Golshan, Nancy U Lin, Craig A Bunnell
BACKGROUND: National guidelines endorse time-dependent quality metrics for breast cancer care. We examined factors associated with delays in chemotherapy initiation at an NCI-Designated Comprehensive Cancer Center. PATIENTS AND METHODS: We identified 523 patients who received postoperative adjuvant chemotherapy between January 2011 and December 2013 at our center. We defined 28 days from last definitive surgery (LDS) to chemotherapy as the target time frame, and an unacceptable delay in chemotherapy initiation (UCD) as greater than 42 days from LDS...
December 2016: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/27915475/how-precisely-can-prostate-cancer-be-managed
#19
REVIEW
Liyan Zhuang, Matthew T Johnson
Progress has been made in applying genetic information to disease management in the postgenomic era, and precision medicine is emerging in prostate cancer management. The prostate health index, the 4-kallikrein (4K) score, and the PCA3, TMPRSS2- ERG, and Prostarix tests have potential for refining prostate cancer screening in conjunction with traditional prostate-specific antigen testing. The Confirm MDx and PCA3 tests have shown promise in identifying men who need be rebiopsied after a primary negative biopsy...
November 2016: International Neurourology Journal
https://www.readbyqxmd.com/read/27899774/-a-review-multigene-assays-for-clinical-utility-in-breast-cancer
#20
Kazuhiro Araki, Yoshinori Ito
Multigene assays that simultaneously measure the expression of various breast cancer genes have been developed to guide the use of adjuvant chemotherapy in early breast cancer. The efficacy of adjuvant therapies depends on the recurrence risk for an individual patient. As a result, accurate prediction of the recurrence risk is vital for precise adjuvant chemotherapy in individual breast cancer patients. The recurrence risk as typically assessed by conventional examination of histological data of immuno-histological biomarkers(ER, PR, HER2, and Ki-67)is not sufficient to select subsets of patients...
November 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
keyword
keyword
24782
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"